Pneumococcal whole-cell and protein-based vaccines: changing the paradigm

References

• Stephens DS. Vaccines for the unvaccinated: protecting the herd. J Infect Dis. 2008;197(5):643–645.
   PubMed Web of Science ®Google Scholar
• Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101(4 Pt 1):604–611.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clinical Infect Dis. 2000;30(1):100–121.
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Lipman HB, et al. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis. 1995;171(4):885–889.
   PubMed Web of Science ®Google Scholar
• Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011;331(6016):430–434.
   PubMed Web of Science ®Google Scholar
• Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28(26):4249–4259.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines. 2015;14(3):413–428.
   PubMed Web of Science ®Google Scholar
• Croucher NJ, Finkelstein JA, Pelton SI, et al. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet. 2013;45(6):656–663.
   PubMed Web of Science ®Google Scholar
• Devine VT, Cleary DW, Jefferies JM, et al. The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine. 2017;35(9):1293–1298.
   PubMed Web of Science ®Google Scholar
• Alderson MR. Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine. 2016;34(26):2959–2961.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452–3459.
   PubMed Web of Science ®Google Scholar
• Janoir C, Lepoutre A, Gutmann L, et al. Insight into resistance phenotypes of emergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolated from invasive disease after 13-valent pneumococcal conjugate vaccine implementation in France. Open Forum Infect Dis. 2016;3(1):ofw020.
   PubMed Web of Science ®Google Scholar
• Galanis I, Lindstrand A, Darenberg J, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47(4):1208–1218.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543.
   PubMed Web of Science ®Google Scholar
• Nakano S, Fujisawa T, Ito Y, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014. Vaccine. 2016;34(1):67–76.
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Weiser JN, Paton JC, et al. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol. 2008;6(4):288–301.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406.
   PubMed Web of Science ®Google Scholar
• Sobanjo-ter Meulen A, Vesikari T, Malacaman EA, et al. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34(2):186–194.
   PubMed Web of Science ®Google Scholar
• McFetridge R, Meulen AS, Folkerth SD, et al. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2015;33(24):2793–2799.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Devaster JM, Leroux-Roels G, et al. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine. 2015;33(4):577–584.
   PubMed Web of Science ®Google Scholar
• Pauksens K, Nilsson AC, Caubet M, et al. Randomized controlled study of pneumococcal vaccine formulations containing PhtD and dPly proteins with alum or adjuvant system AS02V in elderly adults: safety and immunogenicity. Clin Vaccine Immunol. 2014;21(5):651–660.
   PubMed Web of Science ®Google Scholar
• Odutola A, Ota MO, Ogundare EO, et al. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study. Hum Vaccin Immunother. 2016;12(2):393–402.
   PubMed Web of Science ®Google Scholar
• Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine. 2014;32(25):3025–3034.
   PubMed Web of Science ®Google Scholar
• Prymula R, Szenborn L, Silfverdal SA, et al. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants. Vaccine. 2017;35(35PtB):4603–4611.
   Google Scholar
• Kamtchoua T, Bologa M, Hopfer R, et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2013;31(2):327–333.
   PubMed Web of Science ®Google Scholar
• Seiberling M, Bologa M, Brookes R, et al. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. 2012;30(52):7455–7460.
   PubMed Web of Science ®Google Scholar
• Bologa M, Kamtchoua T, Hopfer R, et al. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine. 2012;30(52):7461–7468.
   PubMed Web of Science ®Google Scholar
• Brooks WA, Chang LJ, Sheng X, et al. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study. Vaccine. 2015;33(36):4610–4617.
   PubMed Web of Science ®Google Scholar
• Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother. 2016;12(2):383–392.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Khan MN, Xu Q. Next generation protein based Streptococcus pneumoniae vaccines. Hum Vaccin Immunother. 2016;12(1):194–205.
   PubMed Web of Science ®Google Scholar
• Weiser JN. The pneumococcus: why a commensal misbehaves. J Mol Med (Berl). 2010;88(2):97–102.
   PubMed Web of Science ®Google Scholar
• Dagan R, Lipsitch M. The pneumococcus. In: Tuomanen E, Ed. Changing the ecology of pneumococci with antibiotics and vaccines. Washington, DC: ASM Press; 2004. p. 283–313.
   Google Scholar
• Khan MN, Xu Q, Pichichero ME. Protection against Streptococcus pneumoniae invasive pathogenesis by a protein-based vaccine is achieved by suppression of nasopharyngeal bacterial density during influenza A virus coinfection. Infect Immun. 2017;85(2).
   Web of Science ®Google Scholar
• Slotved HC, Dalby T, Harboe ZB, et al. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon. 2016;2(11):e00198.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–846.
   PubMed Web of Science ®Google Scholar
• Steens A, Caugant DA, Aaberge IS, et al. Decreased carriage and genetic shifts in the streptococcus pneumoniae population after changing the seven-valent to the thirteen-valent pneumococcal vaccine in Norway. Pediatr Infect Dis J. 2015;34(8):875–883.
   PubMed Web of Science ®Google Scholar
• Wilson R, Cohen JM, Reglinski M, et al. Naturally acquired human immunity to pneumococcus is dependent on antibody to protein antigens. PLoS Pathogens. 2017;13(1):e1006137.
   PubMed Web of Science ®Google Scholar
• Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis. 1998;177(2):368–377.
   PubMed Web of Science ®Google Scholar
• Weiser JN, Austrian R, Sreenivasan PK, et al. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun. 1994;62(6):2582–2589.
   PubMed Web of Science ®Google Scholar
• Chai MH, Weiland F, Harvey RM, et al. Proteomic comparisons of opaque and transparent variants of Streptococcus pneumoniae by two dimensional-differential gel electrophoresis. Sci Rep. 2017;7(1):2453.
   PubMedGoogle Scholar
• Overweg K, Pericone CD, Verhoef GG, et al. Differential protein expression in phenotypic variants of Streptococcus pneumoniae. Infect Immun. 2000;68(8):4604–4610.
   PubMed Web of Science ®Google Scholar
• Cundell DR, Weiser JN, Shen J, et al. Relationship between colonial morphology and adherence of Streptococcus pneumoniae. Infect Immun. 1995;63(3):757–761.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt S, Wolff S, Hocke A, et al. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect Immun. 2005;73(8):4653–4667.
   PubMed Web of Science ®Google Scholar
• Magee AD, Yother J. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun. 2001;69(6):3755–3761.
   PubMed Web of Science ®Google Scholar
• Cohen JM, Khandavilli S, Camberlein E, et al. Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation. PloS One. 2011;6(10):e25558.
   PubMed Web of Science ®Google Scholar
• Wu HY, Virolainen A, Mathews B, et al. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog. 1997;23(3):127–137.
   PubMed Web of Science ®Google Scholar
• Turner P, Turner C, Green N, et al. Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. Clin Microbiol Infect. 2013;19(12):E551–558.
   PubMed Web of Science ®Google Scholar
• Dagan R, Juergens C, Trammel J, et al. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration. Vaccine. 2016;34(36):4313–4320.
   PubMed Web of Science ®Google Scholar
• Wolter N, Tempia S, Cohen C, et al. High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia. J Infect Dis. 2014;210(10):1649–1657.
   PubMed Web of Science ®Google Scholar
• Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3):144–154.
   PubMed Web of Science ®Google Scholar
• Bogaert D, Engelen MN, Timmers-Reker AJ, et al. Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study. J Clin Microbiol. 2001;39(9):3316–3320.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest. 2009;119(7):1899–1909.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Kaur R, Casey JR, et al. Antibody response to Streptococcus pneumoniae proteins PhtD, LytB, PcpA, PhtE and Ply after nasopharyngeal colonization and acute otitis media in children. Hum Vaccin Immunother. 2012;8(6):799–805.
   PubMed Web of Science ®Google Scholar
• Granat SM, Ollgren J, Herva E, et al. Epidemiological evidence for serotype-independent acquired immunity to pneumococcal carriage. J Infect Dis. 2009;200(1):99–106.
   PubMed Web of Science ®Google Scholar
• Xu Q, Casey JR, Pichichero ME. Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children. Mucosal Immunol. 2015;8(5):1110–1117.
   PubMed Web of Science ®Google Scholar
• McDaniel LS, Swiatlo E. Should pneumococcal vaccines eliminate nasopharyngeal colonization? mBio. 2016;7:3.
   Web of Science ®Google Scholar
• Hoe E, Boelsen LK, Toh ZQ, et al. Reduced IL-17A secretion is associated with high levels of pneumococcal nasopharyngeal carriage in Fijian children. PloS One. 2015;10(6):e0129199.
   PubMed Web of Science ®Google Scholar
• Moffitt K, Skoberne M, Howard A, et al. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun. 2014;82(5):2079–2086.
   PubMed Web of Science ®Google Scholar
• Campos IB, Herd M, Moffitt KL, et al. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Vaccine. 2017;35(9):1306–1315.
   PubMed Web of Science ®Google Scholar
• Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th Ed. Philadelphia: Elsevier; 2013. p. 447–492.
   Google Scholar
• Gabutti G, Azzari C, Bonanni P, et al. Pertussis. Hum Vaccin Immunother. 2015;11(1):108–117.
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Yadav P, Weinberger DM, et al. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine. 2012;30(29):4316–4322.
   PubMed Web of Science ®Google Scholar
• Higgs R, Higgins SC, Ross PJ, et al. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 2012;5(5):485–500.
   PubMed Web of Science ®Google Scholar
• Bolotin S, Harvill ET, Crowcroft NS. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. Pathog Dis. 2015;73(8):ftv057.
   PubMed Web of Science ®Google Scholar
• Locht C. Pertussis: acellular, whole-cell, new vaccines, what to choose? Expert Rev Vaccines. 2016;15(6):671–673.
   PubMed Web of Science ®Google Scholar
• Zhang L, Prietsch SO, Axelsson I, et al. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014;9:Cd001478.
   Google Scholar
• Singh M, Lingappan K. Whooping cough: the current scene. Chest. 2006;130(5):1547–1553.
   PubMed Web of Science ®Google Scholar
• WHO. Pertussis vaccines: WHO position paper. Releve epidemiologique hebdomadaire. 2010;85(40):385–400.
   PubMedGoogle Scholar
• Lu YJ, Leite L, Goncalves VM, et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine. 2010;28(47):7468–7475.
   PubMed Web of Science ®Google Scholar
• Lu YJ, Gross J, Bogaert D, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathogens. 2008;4(9):e1000159.
   PubMed Web of Science ®Google Scholar
• Alderson M, Malley R, Anderson P, et al. A phase 1 study to assess the safety, tolerability and immunogenicity of inactivated nonencapsulated Streptococcus pneumoniae whole cell vaccine. In: Cripps A, editor. [Abstract ISPPD - 0121]. Pneumonia. Hyderabad; 2014. p. 94.
   Google Scholar
• Briles D, King J, Hale Y, et al. Immune sera from adults immunized with killed whole cell nonencapsulated vaccine protects mice from fatal infection with type 3 pneumococci. In: Cripps A, editor. ISPPD-9/pneumonia. Hyderabad ; 2014. Abstract 0122.
   Google Scholar
• Moffitt KL, Gierahn TM, Lu YJ, et al. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe. 2011;9(2):158–165.
   PubMed Web of Science ®Google Scholar
• Li Y, Gierahn T, Thompson CM, et al. Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathogens. 2012;8(11):e1002989.
   PubMed Web of Science ®Google Scholar
• Hoque SS, Ghosh S, Poxton IR. Differences in intestinal humoral immunity between healthy volunteers from UK and Bangladesh. Eur J Gastroenterol Hepatol. 2000;12(11):1185–1193.
   PubMed Web of Science ®Google Scholar
• Lin A, Bik EM, Costello EK, et al. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PloS One. 2013;8(1):e53838.
   PubMed Web of Science ®Google Scholar
• Usuf E, Bojang A, Hill PC, et al. Nasopharyngeal colonization of Gambian infants by Staphylococcus aureus and Streptococcus pneumoniae before the introduction of pneumococcal conjugate vaccines. New Microbes New Infect. 2016;10:13–18.
   PubMedGoogle Scholar
• Licciardi PV, Russell FM, Balloch A, et al. Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage. Vaccine. 2014;32(20):2321–2327.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Violari A, Klugman KP, et al. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine. 2011;29(40):6994–7001.
   PubMed Web of Science ®Google Scholar
• Lundgren A, Bhuiyan TR, Novak D, et al. Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country. Vaccine. 2012;30(26):3897–3907.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Ten-year study of the stringently defined otitis-prone child in Rochester, NY. Pediatr Infect Dis J. 2016;35(9):1033–1039.
   PubMed Web of Science ®Google Scholar
• Verhoeven D, Xu Q, Pichichero ME. Differential impact of respiratory syncytial virus and parainfluenza virus on the frequency of acute otitis media is explained by lower adaptive and innate immune responses in otitis-prone children. Clinical Infect Dis. 2014;59(3):376–383.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR, Almudevar A, et al. Functional immune cell differences associated with low vaccine responses in infants. J Infect Dis. 2016;213(12):2014–2019.
   PubMed Web of Science ®Google Scholar
• Ren D, Almudevar AL, Pichichero ME. Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children. Hum Vaccin Immunother. 2015;11(2):489–497.
   PubMed Web of Science ®Google Scholar
• Xu Q, Casey JR, Newman E, et al. Otitis-prone children have immunologic deficiencies in naturally acquired nasopharyngeal mucosal antibody response after Streptococcus pneumoniae colonization. Pediatr Infect Dis J. 2016;35(1):54–60.
   PubMed Web of Science ®Google Scholar
• Kaur R, Casey JR, Pichichero ME. Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children. Pediatr Infect Dis J. 2011;30(8):645–650.
   PubMed Web of Science ®Google Scholar
• Verhoeven D, Nesselbush M, Pichichero ME. Lower nasopharyngeal epithelial cell repair and diminished innate inflammation responses contribute to the onset of acute otitis media in otitis-prone children. Med Microbiol Immunol. 2013;202(4):295–302.
   PubMed Web of Science ®Google Scholar
• Gruber MF, Krause PR. Regulating vaccines at the FDA: development and licensure of Zika vaccines. Expert Rev Vaccines. 2017.
   PubMed Web of Science ®Google Scholar
• Hill PC, Cheung YB, Akisanya A, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clinical Infect Dis. 2008;46(6):807–814.
   PubMed Web of Science ®Google Scholar
• Granat SM, Mia Z, Ollgren J, et al. Longitudinal study on pneumococcal carriage during the first year of life in Bangladesh. Pediatr Infect Dis J. 2007;26(4):319–324.
   PubMed Web of Science ®Google Scholar
• Kwambana BA, Barer MR, Bottomley C, et al. Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants. BMC Infect Dis. 2011;11:175.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Ten-year study of acute otitis media in Rochester, NY. Pediatr Infect Dis J. 2016;35(9):1027–1032.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Casey JR, Pichichero ME. Reduced memory CD4+ T-cell generation in the circulation of young children may contribute to the otitis-prone condition. J Infect Dis. 2011;204(4):645–653.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Casey JR, Pichichero ME. Reduced serum IgG responses to pneumococcal antigens in otitis-prone children may be due to poor memory B-cell generation. J Infect Dis. 2012;205(8):1225–1229.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR, Almudevar A. Nonprotective responses to pediatric vaccines occur in children who are otitis prone. Pediatr Infect Dis J. 2013;32(11):1163–1168.
   PubMed Web of Science ®Google Scholar
• Aikins ME, Bazzill J, Moon JJ. Vaccine nanoparticles for protection against HIV infection. Nanomedicine (London, England). 2017;12(6):673–682.
   PubMed Web of Science ®Google Scholar
• Dowling DJ, Scott EA, Scheid A, et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J Allergy Clin Immunol. 2017. pii: S0091-6749(17)30242-7. doi: 10.1016/j.jaci.2016.12.985. [Epub ahead of print]
   PubMedGoogle Scholar
• Zughaier SM. Analysis of novel meningococcal vaccine formulations. Hum Vaccin Immunother. 2017;13(7):1728–1732.
   PubMed Web of Science ®Google Scholar
• Richard K, Mann BJ, Qin A, et al. Monophosphoryl lipid A enhances efficacy of a Francisella tularensis LVS-catanionic nanoparticle subunit vaccine against F. tularensis Schu S4 challenge by augmenting both humoral and cellular immunity. Clinical Vaccine Immuno CVI. 2017;24(3).
   Google Scholar